治験レーダーAI | ||
|---|---|---|
治験 NCT07006142（対象：Upper Endoscopy、GLP1-R-related Disease）は募集中です。詳細は治験レーダーのタイル表示と AI 発見ツールで確認するか、ここで質問してください。 | ||
フィルター基準に一致する試験が1件見つかりました
タイル表示
検索に戻る
メイヨー・クリニックEffect of Prolonged Fasting Time on Gastric Residual Volume in Patients Taking GLP1 Receptor Agonists 150
治験（臨床試験）の詳細は主に英語で提供されていますが、治験レーダーAIがサポートします！「治験解説」をクリックして、選択した言語で試験情報を表示し、議論してください。
治験番号 NCT07006142 は 介入研究 臨床試験 で、Upper Endoscopy、GLP1-R-related Disease に関するものです。現在は 募集中 で、2025年8月1日 から開始しています。150 名の参加者 の募集が計画されています。この試験は メイヨー・クリニック によって主導され、2026年4月30日 に完了予定です。ClinicalTrials.gov からの最新更新日は 2026年2月3日 です。
概要
The aim of this study is to determine whether a modified fasting protocol can reduce the potential risk of aspiration for patients currently prescribed GLP1-RAs.
詳細説明
The overall objective of this project is to identify a reasonable means by which patients on GLP1-RAs can be safely cared for in the perioperative period that can be agreed upon by all groups involved in perioperative patient care. This will be assessed in patients undergoing upper endoscopy specifically since assessment of gastric contents would be minimally invasive for this patient population receiving anesthetic ...もっと見る
公式タイトル
Effect of Prolonged Fasting Time on Gastric Residual Volume in Patients Taking GLP1 Receptor Agonists
疾患名
Upper EndoscopyGLP1-R-related Diseaseその他の研究識別子
- 23-013192
NCT番号
開始日
2025-08-01
最終更新日
2026-02-03
終了予定日
2026-04-30
目標参加者数
150
試験の種類
介入研究
治験の相・段階
該当なし
状況
募集中
キーワード
GLP1 receptor agonists
upper endoscopy
upper endoscopy
主目的
予防
割付方法
該当なし
介入モデル
単一群割当
盲検化
単盲検
群（アーム）／介入
| 参加グループ/群 | 介入/治療法 |
|---|---|
非介入Normal fasting guidelines and not taking GLP1-RAs Patients who are not taking GLP1 RAs (Receptor Agonists) and who will abide by the normal fasting guidelines | 該当なし |
非介入Normal fasting guidelines with GLP1-RAs Patients who are taking GLP1 RAs (Receptor Agonists) for either diabetes or weight loss management who will abide by normal fasting guidelines | 該当なし |
実験的Modified fasting guidelines with GLP1-RAs Patients who are prescribed and taking GLP1 RAs (Receptor Agonists) for either diabetes or weight loss management who follow the modified fasting guidelines. Modified fasting consists of a full-liquid diet 48 hours prior to the procedures, clear liquid diet 24 hours prior to their procedure, and nothing by mouth (NPO) after midnight on the day of their procedure. | Modified Fasting Guidelines Patients will follow a full-liquid diet 48 hours prior to their procedure, clear liquid diet 24 hours prior to their procedure, and nothing by mouth (NPO) after midnight on the day of their procedure |
主要評価項目
副次評価項目
| 評価指標 | 指標の説明 | 時間枠 |
|---|---|---|
Gastric contents | Number of patients who were found to have gastric contents within the stomach during the upper endoscopy. | Baseline |
| 評価指標 | 指標の説明 | 時間枠 |
|---|---|---|
Diagnosis of aspiration within 72 hours of procedure | Whether or not a patient was diagnosed with aspiration will be determined via chart review for 72 hours after the completion of upper endoscopy. A note documenting aspiration or an ICD code associated with aspiration will indicate that this outcome occurred. | From the time of upper endoscopy until 72 hours post-procedure. |
Aspiration pneumonitis diagnosis postoperatively | The number of patients who have a diagnosis of aspiration pneumonitis, as identified by the presence of ICD codes J69.0 or J69.8, postoperatively. | 72 hours after completion of upper endoscopy |
Postprocedural ICU admission | The number of patients who were admitted to the ICU immediately after upper endoscopy. | Immediately after upper endoscopy |
参加アシスタント
適格基準
対象年齢
成人, 高齢者
試験の最低年齢
18 Years
対象性別
全て
- Patients undergoing elective upper endoscopy with gastroenterology team
- Urgent or emergent procedure
- Inclusion of colonoscopy or antegrade small bowel enteroscopy in planned procedure
- Upper GI barium study performed in past 24 hours.
- Gastroparesis
- Achalasia
- Pancreatitis
- Use of outpatient pro-motility medications
- Patient refusal
- Inability for patient to provide own consent
メイヨー・クリニック861 件のアクティブな治験を探索責任者
Krishnan Ramanujan, 主任研究者, Principal Investigator, Mayo Clinic
試験中央連絡先
連絡先: Krishnan Ramanujan, MD, 507-422-4898, [email protected]
1 1カ国の場所
Minnesota
Mayo Clinic in Rochester, Rochester, Minnesota, 55905, United States
Krishnan Ramanujan, MD, 連絡先, 507-422-4898, [email protected]
募集中